Affibody has announced that it has decided to initiate Phase II development with ABY-035, which is the company’s proprietary psoriasis program.
"This Affibody molecule, ABY-035, has been specifically designed to capture the unique aspects of the Affibody technology. It is a bi-specific construct with extraordinary affinity and confirmed antibody-like half-life. The initial results from our patient arms in an ongoing Phase I/II study confirm a very rapid and sustained clinical benefit for patients. With these results we have decided to advance the project into Phase II development and expect recruitment to commence during H2 2017." says David Bejker, CEO of Affibody.